JP2023530919A5 - - Google Patents

Info

Publication number
JP2023530919A5
JP2023530919A5 JP2022576374A JP2022576374A JP2023530919A5 JP 2023530919 A5 JP2023530919 A5 JP 2023530919A5 JP 2022576374 A JP2022576374 A JP 2022576374A JP 2022576374 A JP2022576374 A JP 2022576374A JP 2023530919 A5 JP2023530919 A5 JP 2023530919A5
Authority
JP
Japan
Prior art keywords
cells
optionally
cell population
ipscs
isolated cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022576374A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023530919A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/037594 external-priority patent/WO2021257679A1/en
Publication of JP2023530919A publication Critical patent/JP2023530919A/ja
Publication of JP2023530919A5 publication Critical patent/JP2023530919A5/ja
Pending legal-status Critical Current

Links

JP2022576374A 2020-06-17 2021-06-16 多能性幹細胞の製造のための材料及び方法 Pending JP2023530919A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063040392P 2020-06-17 2020-06-17
US202063040398P 2020-06-17 2020-06-17
US202063040374P 2020-06-17 2020-06-17
US202063040373P 2020-06-17 2020-06-17
US202063040397P 2020-06-17 2020-06-17
US63/040,374 2020-06-17
US63/040,398 2020-06-17
US63/040,392 2020-06-17
US63/040,397 2020-06-17
US63/040,373 2020-06-17
PCT/US2021/037594 WO2021257679A1 (en) 2020-06-17 2021-06-16 Materials and methods for the manufacture of pluripotent stem cells

Publications (2)

Publication Number Publication Date
JP2023530919A JP2023530919A (ja) 2023-07-20
JP2023530919A5 true JP2023530919A5 (enExample) 2024-06-24

Family

ID=79023159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022576374A Pending JP2023530919A (ja) 2020-06-17 2021-06-16 多能性幹細胞の製造のための材料及び方法

Country Status (10)

Country Link
US (2) US11981932B2 (enExample)
EP (1) EP4168433A4 (enExample)
JP (1) JP2023530919A (enExample)
KR (1) KR20230025005A (enExample)
CN (1) CN116157510A (enExample)
AU (1) AU2021292511A1 (enExample)
CA (1) CA3187267A1 (enExample)
IL (1) IL298909A (enExample)
TW (1) TW202214844A (enExample)
WO (1) WO2021257679A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200017837A1 (en) * 2017-02-03 2020-01-16 National University Corporation Kobe University Method For Producing Induced Pluripotent Stem Cells
CA3203232A1 (en) * 2020-12-25 2022-06-30 Kyoto University Method for producing naive human ips cells from somatic cells
US20240010991A1 (en) 2022-07-01 2024-01-11 Janssen Biotech, Inc. Materials and methods for bioengineered ipsc populations
EP4580661A1 (en) 2022-09-02 2025-07-09 Janssen Biotech, Inc. Materials and processes for bioengineering cellular hypoimmunogenicity
WO2024127335A1 (en) * 2022-12-15 2024-06-20 Janssen Biotech, Inc. Materials, methods and systems for cellular redifferentiation and expansion

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3378250D1 (en) 1982-04-22 1988-11-24 Ici Plc Continuous release formulations
IL68218A (en) 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5041138A (en) 1986-11-20 1991-08-20 Massachusetts Institute Of Technology Neomorphogenesis of cartilage in vivo from cell culture
US4846835A (en) 1987-06-15 1989-07-11 Grande Daniel A Technique for healing lesions in cartilage
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
WO1991006287A1 (en) 1989-11-06 1991-05-16 Enzytech, Inc. Protein microspheres and methods of using them
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5646008A (en) 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
US5723331A (en) 1994-05-05 1998-03-03 Genzyme Corporation Methods and compositions for the repair of articular cartilage defects in mammals
US5698446A (en) 1994-09-07 1997-12-16 Chiron Corporation Methods and compositions for inhibiting production of replication competent virus
WO2000032776A2 (en) 1998-12-01 2000-06-08 Genentech, Inc. Secreted amd transmembrane polypeptides and nucleic acids encoding the same
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
WO1999037681A2 (en) 1998-01-26 1999-07-29 Unilever Plc Method for producing antibody fragments
AU2291700A (en) 1999-01-19 2000-08-07 Unilever Plc Method for producing antibody fragments
AU4418900A (en) 1999-04-16 2000-11-02 Celltech Therapeutics Limited Synthetic transmembrane components
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
CA2457636C (en) 2001-08-10 2012-01-03 Aberdeen University Antigen binding domains
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
JP2007528723A (ja) 2003-08-22 2007-10-18 メディミューン，インコーポレーテッド 抗体のヒト化
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
SG169348A1 (en) 2006-01-25 2011-03-30 Univ Erasmus Medical Ct Generation of heavy-chain only antibodies in transgenic animals
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
DK2509409T3 (en) 2009-12-10 2016-11-14 Regeneron Pharma MICE, WHICH PRODUCES HEAVY CHAIN ANTIBODIES
US9732128B2 (en) * 2010-10-22 2017-08-15 Biotime, Inc. Methods of modifying transcriptional regulatory networks in stem cells
RU2658485C2 (ru) 2012-10-24 2018-06-21 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы м971
WO2015137885A1 (en) * 2014-03-11 2015-09-17 Agency For Science, Technology And Research Method for inducing pluripotency in a hematopoietic cell
CN106255410B (zh) 2014-03-21 2020-01-10 瑞泽恩制药公司 产生单结构域结合蛋白的非人动物
CA2945620C (en) 2014-04-14 2022-12-06 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
WO2015164740A1 (en) * 2014-04-24 2015-10-29 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
MX2017001079A (es) 2014-07-24 2017-09-12 Bluebird Bio Inc Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
IL301458A (en) 2014-12-24 2023-05-01 Autolus Ltd A cell that simultaneously expresses a chimeric antigen receptor (CAR) of 19CD and 22CD
WO2018067992A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
US20200017837A1 (en) * 2017-02-03 2020-01-16 National University Corporation Kobe University Method For Producing Induced Pluripotent Stem Cells
JP7092281B2 (ja) * 2017-02-07 2022-06-28 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 多能性幹細胞から模倣自然免疫細胞を生成する方法及びキット

Similar Documents

Publication Publication Date Title
US10435711B2 (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
Drozd et al. Generation of human iPSCs from cells of fibroblastic and epithelial origin by means of the oriP/EBNA-1 episomal reprogramming system
AU2019203335B2 (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
JP6933898B2 (ja) 養子細胞治療製品を製造するための誘導多能性幹細胞の適用
US10155929B2 (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger RNA
Sadahiro et al. Direct cardiac reprogramming: progress and challenges in basic biology and clinical applications
Martins et al. The current status of iPS cells in cardiac research and their potential for tissue engineering and regenerative medicine
Netsrithong et al. Engineered T cells from induced pluripotent stem cells: from research towards clinical implementation
JP7224021B2 (ja) 人工多能性幹細胞の作製方法
Abujarour et al. Generation of skeletal muscle cells from pluripotent stem cells: advances and challenges
Smith et al. Regeneration through reprogramming adult cell identity in vivo
CN115087732B (zh) 来自人T细胞来源的iPS细胞的细胞毒性T细胞
KR102361849B1 (ko) 합성 메신저 rna를 사용한 인간-유도된 만능 줄기 세포의 무-피더 유래
Brändl et al. Stem cell reprogramming: basic implications and future perspective for movement disorders
Šarić et al. Stem cells and nuclear reprogramming
RU2025101461A (ru) Материалы и способы для биоинженерных популяций ipsc
Fraga et al. Use of human embryonic stem cells in therapy
HK40015744A (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
HK40015744B (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna
HK40013817B (en) Feeder-free derivation of human-induced pluripotent stem cells with synthetic messenger rna